通过整合海量数据、结合人工智能的深度学习和高效分析能力，并将其融入药物研发进程，诺华正逐步 成为生成式生物学前沿创新的核心推动者之一。此前，诺华已经与微软建立合作，将机器学习应用于药 物研发。 6月24日至26日，世界经济论坛第十六届新领军者年会（夏季达沃斯论坛）在天津举行。本届年会以"新 时代企业家精神"为主题，汇聚来自全球1700余位政商领袖、专家学者共同探讨如何以企业家精神和创 新驱动经济增长与探索产业升级新路径等话题。诺华中国区总裁兼董事总经理李尧受邀参会，并围 绕"智造"为医药研发带来革新等话题分享了见解。 将人工智能融入药品研发 随着前沿技术的不断进展，人工智能和生成式生物学带来的变革，正在重塑"从分子到药物"的旅程。越 来越多的医药企业开始应用人工智能来提升全流程效率。以"创新"为核心竞争力的诺华，也在拥抱这一 变革。 李尧表示，作为全球医药健康行业领跑者，诺华始终秉承'以患者为中心'的核心理念，希望通过创新和 前沿技术创想医药未来。人工智能与生成式生物学不仅是研发工具，更是开启生物医学新纪元的催化 剂。他也坚信，借助这些前沿技术的创新力量，联合全球特别是中国本土的创新资源，将会为药物研发 带来 ...

Basel, June 25, 2025 – Novartis today announced that its previously announced tender offer (the “Offer”) by Redwood Merger Sub Inc., a Delaware corporation and an indirect wholly owned subsidiary of Novartis (“Purchaser”), to acquire all of the outstanding shares of common stock, par value $0.001 per share (the “Shares”), of Regulus Therapeutics Inc. (“Regulus”), in exchange for (i) $7.00 in cash per share, subject to any applicable withholding and without interest thereon, plus (ii) one contingent value ri ...

Investment Rating - The report maintains a "Positive" investment rating for the industry [9] Core Insights - PCSK9 inhibitors are emerging as a key target for long-term lipid management, with seven approved products globally by June 2025, including monoclonal antibodies and siRNA drugs [2][6] - The report highlights the diverse technological pathways and expanding application scenarios for PCSK9 inhibitors, with ongoing innovations aimed at improving patient compliance [2][7] - Clinical trials have demonstrated significant efficacy and safety for various PCSK9 inhibitors, with notable LDL-C reductions observed in multiple studies [8][46] Summary by Sections Mechanism and Importance - PCSK9, discovered in 2003, plays a crucial role in regulating LDL-C levels and is a significant factor in atherosclerotic cardiovascular disease (ASCVD) [6][15] - Current treatments, primarily statins, are insufficient for about half of patients, creating a demand for PCSK9 inhibitors as complementary therapies [6][15] Market Landscape - As of June 2025, seven PCSK9 inhibitors have been approved, with major pharmaceutical companies like Amgen, Sanofi, and domestic firms such as HengRui and Junshi actively involved [7][29] - The report notes the submission of a new non-antibody fusion protein to the FDA and the advancement of Merck's oral PCSK9 inhibitor Enlicitide into Phase III trials, indicating a broadening of treatment options [7][29] Clinical Efficacy - Clinical trials for PCSK9 inhibitors have shown substantial LDL-C reductions, with specific data indicating reductions of 62.2% for HengRui's drug and 61.9% for Innovent's drug [8][46] - The oral PCSK9 inhibitor Enlicitide has also demonstrated superior efficacy compared to placebo and other oral medications, validating its clinical value [8][60] Investment Perspective - The report suggests that the healthcare sector will continue to see innovation-driven growth, particularly in companies with strong cash flows and innovative capabilities [64] - It emphasizes the importance of breakthrough therapies and technological advancements in driving sector interest, particularly in immunotherapy and novel drug delivery systems [64]

Core Points - Novartis announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act in relation to its tender offer to acquire Regulus Therapeutics Inc. [1][2] - The tender offer includes $7.00 in cash per share and one contingent value right (CVR) per share, which represents the right to receive an additional $7.00 upon achieving a regulatory milestone [1][2]. - The expiration of the HSR Act waiting period is a necessary condition for the completion of the merger agreement dated April 29, 2025 [2]. Tender Offer Details - The offer will expire one minute past 11:59 p.m. New York City Time on June 24, 2025, unless extended or terminated earlier [2]. - The completion of the transaction requires validly tendered shares that, along with shares owned by Novartis and its subsidiaries, represent at least one more than 50% of the total outstanding shares [2]. Additional Information - Novartis and its subsidiary filed a tender offer statement with the U.S. Securities and Exchange Commission (SEC), and Regulus filed a solicitation/recommendation statement regarding the tender offer [3]. - Investors are encouraged to read the tender offer materials and the solicitation/recommendation statement for important information before making decisions [4].

5月底，拜耳和诺华新的抗VEGF药物相继在国内获批，在传统抗VEGF药物主导眼底疾病治疗市场十年 后，市场迎来了一丝新意。 近年来，随着双靶点药物（法瑞西单抗）、长效制剂（布西珠单抗）以及基因疗法（如AAV载体药 物）的接连登场，眼底治疗周期从"月注射"延至"季度注射"，疗效与依从性革命也在重塑临床标准。再 加上医保的助推，使得市场增量得以持续释放。 这场由技术、价格和渠道三维驱动的眼底药物竞争，正从红海厮杀走向价值重构，唯有突破"跟随式创 新"的企业，方能占据市场的制高点。 文｜动脉网 眼底治疗市场正孕育着一场大的变革。 被搅浑的眼底治疗市场 上市10多年的雷珠单抗开始显露疲态。 仰仗着原研以及先发的优势，诺华的雷珠单抗本来牢牢把持着国内眼底治疗市场的头把交椅，可随着竞 争者的不断涌现，市场起了变化。从康弘（康柏西普）和拜耳（阿柏西普），到2024年获批的罗氏（法 瑞西单抗）和齐鲁制药（阿柏西普、雷珠单抗仿制药）的加入，雷珠单抗已经疲于应对。 雷 珠单抗近10年销售情况及增长率，图源摩熵医药 据摩熵医药数据显示，雷珠单抗在经历10年的高速增长后，销售开始放缓。尽管2024年仍然取得了同比 1.37%的增长， ...

Industry Overview - The Zacks Large Cap Pharmaceuticals industry includes major global companies developing multi-million-dollar drugs across various therapeutic areas such as neuroscience, cardiovascular, metabolism, rare diseases, immunology, and oncology [4] - Continuous innovation and significant investment in R&D are defining characteristics of these companies, with regular mergers and acquisitions being common [4][5] Current Market Conditions - The industry has shown resilience amid broader macroeconomic uncertainties, with a year-to-date performance increase of 3.9%, outperforming the Zacks Medical Sector's decline of 1.5% and the S&P 500's rise of 1.7% [14] - The current forward 12-month price-to-earnings (P/E) ratio for the industry is 15.65X, lower than the S&P 500's 21.89X and the Zacks Medical Sector's 19.31X, indicating potential value [17] Key Players and Performance - **Bayer**: Key drugs like Nubeqa and Kerendia are driving growth, with plans for new drug launches in 2025. The stock has risen 61.9% year-to-date, with 2025 EPS estimates increasing from $1.19 to $1.25 [20][22] - **Pfizer**: Strengthened its oncology position with the acquisition of Seagen. Despite challenges from declining COVID-19 product sales and patent expirations, non-COVID operational revenues are improving. The stock has lost 4.2% year-to-date, but 2025 EPS estimates have risen from $2.98 to $3.06 [25][26][28] - **Novartis**: Following the separation of Sandoz, it has a strong portfolio with drugs like Kisqali and Leqvio. The stock has risen 25.6% year-to-date, with 2025 EPS estimates increasing from $8.46 to $8.74 [31][32] - **AbbVie**: Successfully transitioned from the loss of exclusivity of Humira with new drugs like Skyrizi and Rinvoq. The stock has risen 9.5% year-to-date, with stable 2025 EPS estimates at $12.28 [35][37] - **Sanofi**: Dupixent is a key growth driver, supported by a strong vaccine portfolio. The stock has risen 6.3% year-to-date, with 2025 EPS estimates increasing from $4.43 to $4.56 [40][42] M&A and Innovation Trends - The industry is characterized by aggressive M&A activity, with large pharmaceutical companies acquiring innovative small and mid-cap biotech firms to enhance their pipelines [6][7] - Recent notable M&A activity includes Sanofi's offer to acquire Blueprint Medicines for approximately $9.5 billion, indicating continued robust M&A activity expected throughout the year [8]

Shares of Novartis (NVS) have been strong performers lately, with the stock up 11.4% over the past month. The stock hit a new 52-week high of $120.92 in the previous session. Novartis has gained 24.1% since the start of the year compared to the -1.5% move for the Zacks Medical sector and the 2.8% return for the Zacks Large Cap Pharmaceuticals industry.What's Driving the Outperformance?The stock has a great record of positive earnings surprises, as it hasn't missed our earnings consensus estimate in any of ...

Novartis AG NVS on Thursday released results from APPULSE-PNH, a Phase 3B study evaluating the efficacy and safety of twice-daily oral monotherapy Fabhalta (iptacopan) in adult patients with paroxysmal nocturnal hemoglobinuria (PNH) with Hb levels ≥10g/dL who switched from anti-C5 therapies (eculizumab or ravulizumab).The company released topline data in December 2024.What Happened: PNH is a rare complement-mediated blood disorder. People with PNH have an acquired mutation in some of their hematopoietic ste ...

Basel, June 12, 2025 – Novartis announced positive results from APPULSE-PNH, a Phase IIIB study evaluating the efficacy and safety of twice-daily oral monotherapy Fabhalta® (iptacopan) in adult patients with paroxysmal nocturnal hemoglobinuria (PNH) with Hb levels ≥10g/dL who switched from anti-C5 therapies (eculizumab or ravulizumab)1. After 24 weeks of treatment with Fabhalta, the Hb level improved on average by 2.01 g/dL (95% CI, 1.74, 2.29) with most patients achieving normal or near-normal levels 1. Da ...

It is estimated that approximately 10-20 people per million worldwide live with PNH. Although PNH can develop at any age, it is often diagnosed in people between 30-40 years old. In the Phase IIIB APPULSE-PNH study, adult patients with paroxysmal nocturnal hemoglobinuria (PNH) who switched to Fabhalta experienced clinically meaningful improvements in hemoglobin (Hb) levels of 2.01 g/dL on average APPULSE-PNH evaluated Fabhalta in a population with higher baseline hemoglobin (Hb) levels than those enrolled i ...